"For the first time in 20 years." That is the FDA's own phrasing, and if anything it undersells the thing. On June 9, 2026, the agency finalized bemotrizinol, sold as PARSOL Shield by dsm-firmenich, as an active ingredient for over-the-counter sunscreens, at concentrations up to 6 percent, for adults and children six months and older. It is the first new active ingredient added to the FDA's sunscreen monograph, the agency's official list of ingredients cleared for use in over-the-counter sunscreens, since the late 1990s, which is closer to a generation than to twenty years. The filter is not new. The wait is.
Bemotrizinol has been in European and Asian sunscreens since 1999, sold as Tinosorb S by BASF and as PARSOL Shield by DSM, now dsm-firmenich after DSM and Firmenich merged in 2023. It is a photostable, broad-spectrum filter: it absorbs both UVA and UVB and, unlike avobenzone (one of only two UVA options US formulators have had, alongside mineral zinc oxide), it does not fall apart in sunlight. A genuinely useful molecule.
None of that is the story. The story is why a chemical the rest of the world settled decades ago took the US until now.
The short answer is a classification. In the US, sunscreen is regulated as an over-the-counter drug; in Europe it is a cosmetic. Drug status means the ingredient maker pays for every efficacy and safety study the agency asks for, and the FDA kept asking. Bemotrizinol first entered the queue under the Time and Extent Application process created in 2002; it was one of eight European filters in that queue, and none of the eight ever cleared that route. Congress tried to force the issue with the Sunscreen Innovation Act of 2014, which directed the FDA to review the same eight molecules. The agency responded by requiring modern skin-absorption studies and maximal usage trials, the tests that measure how much of an active reaches the bloodstream under heavy, real-world application; the queue stalled again. By C&EN's accounting, dsm-firmenich spent at least $18 million over more than two decades getting this one filter across the line.
So when FDA Commissioner Marty Makary talks about modernizing over-the-counter drug regulation, keep the math in view. The molecule did not change; it was already good in 1999. What changed is that the paperwork finally had somewhere to go: bemotrizinol is the first ingredient approved through the streamlined administrative-order pathway the CARES Act set up in 2020. Once that pathway existed, the final order ran seven months from proposal to finish. The molecule waited more than twenty years for a filing process that took seven months.
Here is the part the headlines skip. Approval does not put anything in your cart. Manufacturers may begin using bemotrizinol on August 9, 2026, but reformulating, testing, and manufacturing a new SPF line takes time. Kenvue, which owns Neutrogena and Aveeno, has said Neutrogena will "integrate this filter into its sunscreen innovation pipeline," in the words of Asha Patel Shah, the company's North American head of medical affairs for skin health and baby. That is a plan, not a product. The realistic answer to what reaches shelves this year is very little, and probably nothing before late 2026.
HHS Secretary Robert F. Kennedy Jr. said the clearance "will increase competition and consumer confidence." Weigh that first claim against the machinery. dsm-firmenich holds an 18-month exclusivity window, which hands the ingredient and its licensees the US market to themselves into 2028. And dsm-firmenich's own regulatory manager, Carl D'Ruiz, told C&EN the company has no immediate plans to seek US approval for the other filters it sells abroad, because eighteen months of exclusivity makes a thin business case for spending years and millions on the next one. He also made the practical point that brands "can't simply import sunscreens they already make for other regions," because those formulas usually lean on filters the FDA still has not approved. One molecule cleared. The other seven are still parked.
What bemotrizinol actually buys you is worth stating without inflation. It is a chemical filter, so it does not leave the white cast minerals do, and dsm-firmenich positions it to pair with zinc oxide for high-SPF formulas that stay wearable, which matters more than it sounds: the best sunscreen is the one you will reapply, and texture is compliance, not vanity. Dermatologists have been measured about it. "Bemotrizinol is an exciting addition, but no sunscreen ingredient is magic," Dr. Mona Gohara of Yale told PolitiFact. The FDA's data shows it is minimally absorbed at up to 6 percent, below the threshold the agency treats as systemic exposure, which is what the agency measured rather than a blanket safety verdict, and also exactly the kind of study the other filters were told to produce and mostly have not.
So take the announcement for what it is. Not a breakthrough at the bench, a molecule that was already good in 1999. What changed is a regulatory door, opened once, for one company, on a clock. Watch the label when it finally arrives, check the percentage, and notice what "for the first time in 20 years" actually means.
